GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (STU:8EM) » Definitions » Cyclically Adjusted Price-to-FCF

Editas Medicine (STU:8EM) Cyclically Adjusted Price-to-FCF : (As of Sep. 22, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Editas Medicine Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Editas Medicine Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Editas Medicine's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Editas Medicine Cyclically Adjusted Price-to-FCF Chart

Editas Medicine Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Editas Medicine Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Editas Medicine's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Editas Medicine's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Editas Medicine's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Editas Medicine's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Editas Medicine's Cyclically Adjusted Price-to-FCF falls into.



Editas Medicine Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Editas Medicine's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Editas Medicine's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-0.683/132.5538*132.5538
=-0.683

Current CPI (Jun. 2024) = 132.5538.

Editas Medicine Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201409 0.000 100.428 0.000
201412 -0.196 99.070 -0.262
201503 -0.374 99.621 -0.498
201506 1.149 100.684 1.513
201509 -0.700 100.392 -0.924
201512 -0.216 99.792 -0.287
201603 -0.426 100.470 -0.562
201606 -0.279 101.688 -0.364
201609 -0.446 101.861 -0.580
201612 -0.381 101.863 -0.496
201703 1.772 102.862 2.283
201706 -0.578 103.349 -0.741
201709 -0.584 104.136 -0.743
201712 -0.503 104.011 -0.641
201803 -0.414 105.290 -0.521
201806 -0.330 106.317 -0.411
201809 -0.159 106.507 -0.198
201812 -0.002 105.998 -0.003
201903 -0.539 107.251 -0.666
201906 -0.493 108.070 -0.605
201909 -0.531 108.329 -0.650
201912 0.678 108.420 0.829
202003 -0.932 108.902 -1.134
202006 -0.525 108.767 -0.640
202009 -0.766 109.815 -0.925
202012 -0.547 109.897 -0.660
202103 -0.631 111.754 -0.748
202106 -0.509 114.631 -0.589
202109 -0.537 115.734 -0.615
202112 -0.485 117.630 -0.547
202203 -0.682 121.301 -0.745
202206 -0.530 125.017 -0.562
202209 -0.714 125.227 -0.756
202212 -0.589 125.222 -0.623
202303 -0.510 127.348 -0.531
202306 -0.518 128.729 -0.533
202309 -0.410 129.860 -0.419
202312 -0.264 129.419 -0.270
202403 -0.581 131.776 -0.584
202406 -0.683 132.554 -0.683

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Editas Medicine  (STU:8EM) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Editas Medicine Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Editas Medicine's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Editas Medicine Business Description

Industry
Traded in Other Exchanges
Address
11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Editas Medicine Headlines

No Headlines